The University of Maryland, Baltimore has granted a startup company, Pataigin LLC, worldwide, exclusive licensing rights to patents and technology to develop a method to quickly and accurately identify dangerous pathogens.
Erik Nilsson, who is currently CEO of Deurion, a software development company that developed new technologies for mass spectrometry, bioinformatics and microfluidics, will serve as Pataigin’s CEO and president.
Robert Ernst, associate professor of microbial pathogenesis at University of Maryland School of Dentistry, and David Goodlett, professor of pharmaceutical sciences at University of Maryland School of Pharmacy, are inventors of patents being licensed by Pataigin. The University of Washington is also a co-owner on one of the patents Pataigin is licensing. Ernst and Goodlett will serve on the company’s leadership team.
The technology will allow pathogen identification directly from tissues like blood, urine, and wounds, without the need for cell culture, according to a statement from The University of Maryland, Baltimore. It also can differentiate between drug-susceptible and drug-resistant variants, allowing for quicker medical treatment decisions and containment of dangerous pathogens.